Multihance (Gadobenate Dimeglumine)

Multihance is used as a gadolinium‑based contrast agent for magnetic resonance imaging procedures.

• Brain and spinal cord MRI: provides enhanced T1‑weighted images to delineate lesions, tumors and vascular structures.
• Liver MRI: improves lesion detection and characterization by increasing contrast between hepatic tissue and lesions.
• Cardiovascular MRI: highlights myocardial perfusion and vascular anatomy for assessment of cardiac function and disease.
• MR angiography: enhances visualization of arterial and venous vessels to aid in diagnosing stenosis or aneurysm.
• Whole‑body MRI: delivers uniform contrast throughout the body to facilitate screening for metastatic disease.

• Multihance contains gadobenate dimeglumine, a paramagnetic gadolinium complex that shortens the T1 relaxation time of nearby water protons. After intravenous injection, the agent distributes in the extracellular fluid and transiently accumulates in vascular and interstitial spaces. Its high relaxivity increases signal intensity on T1‑weighted MRI sequences, producing brighter images of tissues and blood vessels, thereby improving diagnostic contrast.

Adverse reactions to Multihance are generally infrequent but may occur following intravenous administration.

Common Side Effects

• Nausea: mild, transient stomach upset.
• Headache: temporary discomfort that usually resolves spontaneously.
• Injection site discomfort: mild pain or warmth at the infusion site.
• Warm sensation: brief feeling of heat throughout the body during injection.

Serious or Rare Side Effects

• Allergic reaction: hives, rash, itching, or swelling indicating hypersensitivity.
• Anaphylaxis: severe systemic reaction that can be life‑threatening.
• Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment.
• Severe hypotension: marked drop in blood pressure during or after injection.

When using Multihance, clinicians should observe specific precautions to minimize risk and ensure optimal imaging results.

• Renal function assessment: evaluate glomerular filtration rate before administration, especially in patients with kidney disease.
• Pregnancy considerations: avoid use unless clearly needed, as safety category C indicates potential risk to the fetus.
• Breastfeeding guidance: advise caution; limited data, consider withholding breastfeeding for a short period after injection.
• Prior contrast reactions: review patient history for previous gadolinium or iodine contrast agent hypersensitivity.
• Concomitant nephrotoxic drugs: monitor closely when used with medications that may affect kidney function.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Multihance may interact with certain agents or conditions that affect its safety profile.

Major Interactions (Avoid)

• Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid or use alternative contrast.
• Calcium‑binding agents (e.g., calcium gluconate) administered concurrently: may reduce contrast enhancement quality.

Moderate Interactions (Monitor Closely)

• Other gadolinium‑based agents: cumulative gadolinium exposure may increase toxicity risk.
• High‑dose steroids: may alter distribution of contrast agent.
• Diuretics: may affect renal clearance of gadolinium, requiring monitoring of renal function.